Genmab A/S
GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$50.60−0.75 (-1.46%)
Close on Nov 20, 2026
Genmab A/S Development & CMC Stage R&D Expense by Year
Development & CMC Stage R&D Expense ($M)
Genmab A/S Development & CMC Stage R&D Expense: $598M in FY2025, up 15.9% from a year earlier.
Latest, FY2025
598
Period ended Dec 31, 2025
Change on a year earlier
+15.9%
516 in FY2024
History
3 years
Since FY2023
Sources
1
Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.)
Where the FY2025 figure comes from
“|| Development and contract manufacturing² | 598 | 516 | 337 | 16 % | 53 %”
Source: Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗
annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Development & CMC Stage R&D Expense ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 598 | +15.9% | Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗ |
| FY2024 | Dec 31, 2024 | 516 | +53.1% | Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗ |
| FY2023 | Dec 31, 2023 | 337 | – | Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗ |
Cite this data
StockData. (2026). Genmab A/S Development & CMC Stage R&D Expense ($M), annual FY2023–FY2025 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/rd-func-dev-cmc
See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.
See a number that looks wrong?